WO2005076000A8 - Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr - Google Patents

Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr

Info

Publication number
WO2005076000A8
WO2005076000A8 PCT/ES2005/000046 ES2005000046W WO2005076000A8 WO 2005076000 A8 WO2005076000 A8 WO 2005076000A8 ES 2005000046 W ES2005000046 W ES 2005000046W WO 2005076000 A8 WO2005076000 A8 WO 2005076000A8
Authority
WO
WIPO (PCT)
Prior art keywords
predisposition
development
assessing risk
pathology related
epcr
Prior art date
Application number
PCT/ES2005/000046
Other languages
English (en)
French (fr)
Other versions
WO2005076000A1 (es
Inventor
Santos Jose Hermida
Diaz Ramon Montes
Linares Veronica Hurtado
Original Assignee
Proyecto Biomedicina Cima Sl
Santos Jose Hermida
Diaz Ramon Montes
Linares Veronica Hurtado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl, Santos Jose Hermida, Diaz Ramon Montes, Linares Veronica Hurtado filed Critical Proyecto Biomedicina Cima Sl
Priority to EP05701698A priority Critical patent/EP1722229B8/en
Priority to AU2005210776A priority patent/AU2005210776A1/en
Priority to AT05701698T priority patent/ATE445163T1/de
Priority to JP2006551864A priority patent/JP2007520713A/ja
Priority to BRPI0506635-2A priority patent/BRPI0506635A/pt
Priority to CA002555783A priority patent/CA2555783A1/en
Priority to US10/588,740 priority patent/US20070141625A1/en
Priority to DE602005017016T priority patent/DE602005017016D1/de
Priority to MXPA06008799A priority patent/MXPA06008799A/es
Publication of WO2005076000A1 publication Critical patent/WO2005076000A1/es
Publication of WO2005076000A8 publication Critical patent/WO2005076000A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para detectar la presencia de niveles elevados de autoanticuerpos frente al receptor endotelial de la PC/PC activada (EPCR), caracterizado porque comprende la detección y cuantificación in vitro de autoanticuerpos frente al EPCR en una muestra.
PCT/ES2005/000046 2004-02-06 2005-02-03 Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr WO2005076000A1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP05701698A EP1722229B8 (en) 2004-02-06 2005-02-03 Method of assessing risk of and predisposition to the development of a pathology related to the presence of anti-epcr antibodies
AU2005210776A AU2005210776A1 (en) 2004-02-06 2005-02-03 Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-EPCR autoantibodies
AT05701698T ATE445163T1 (de) 2004-02-06 2005-02-03 Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln
JP2006551864A JP2007520713A (ja) 2004-02-06 2005-02-03 抗ｅｐｃｒ抗体の存在に関連する病状の進展の危険性および傾向の評価方法
BRPI0506635-2A BRPI0506635A (pt) 2004-02-06 2005-02-03 método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc
CA002555783A CA2555783A1 (en) 2004-02-06 2005-02-03 Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
US10/588,740 US20070141625A1 (en) 2005-02-03 2005-02-03 Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
DE602005017016T DE602005017016D1 (de) 2004-02-06 2005-02-03 Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln
MXPA06008799A MXPA06008799A (es) 2004-02-06 2005-02-03 Metodo para evaluar el riesgo y la predisposicion desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400269A ES2239532B1 (es) 2004-02-06 2004-02-06 Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
ESP200400269 2004-02-06

Publications (2)

Publication Number Publication Date
WO2005076000A1 WO2005076000A1 (es) 2005-08-18
WO2005076000A8 true WO2005076000A8 (es) 2005-10-27

Family

ID=34833893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2005/000046 WO2005076000A1 (es) 2004-02-06 2005-02-03 Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr

Country Status (12)

Country Link
EP (1) EP1722229B8 (es)
JP (1) JP2007520713A (es)
CN (1) CN1954216A (es)
AT (1) ATE445163T1 (es)
AU (1) AU2005210776A1 (es)
BR (1) BRPI0506635A (es)
CA (1) CA2555783A1 (es)
DE (1) DE602005017016D1 (es)
ES (1) ES2239532B1 (es)
MX (1) MXPA06008799A (es)
RU (1) RU2375716C2 (es)
WO (1) WO2005076000A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
CA2760903A1 (en) * 2009-05-05 2010-11-11 Irun R. Cohen Means and methods for recognizing the development of cardiovascular disease in an individual
WO2011099012A1 (en) * 2010-02-12 2011-08-18 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
CN103299190B (zh) * 2010-10-18 2017-02-15 雀巢产品技术援助有限公司 确定抗药物抗体同种型的方法
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
CA2825765C (en) * 2011-02-02 2020-03-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis
RU2586412C2 (ru) * 2012-06-09 2016-06-10 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ оценки риска возникновения патологии беременности
RU2517051C1 (ru) * 2013-01-09 2014-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин
CN104655860A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种类风湿性关节炎的诊断标志
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
EP4085252A1 (en) * 2019-12-30 2022-11-09 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666352B2 (en) * 1992-02-05 1996-02-08 Takao Koike Solid-phase reagent and assay method for measuring antibodies specific to antiphospholipid syndrome
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide

Also Published As

Publication number Publication date
RU2375716C2 (ru) 2009-12-10
EP1722229B8 (en) 2009-11-25
RU2006132064A (ru) 2008-03-20
CN1954216A (zh) 2007-04-25
JP2007520713A (ja) 2007-07-26
ES2239532B1 (es) 2006-11-01
EP1722229B1 (en) 2009-10-07
ES2239532A1 (es) 2005-09-16
AU2005210776A1 (en) 2005-08-18
BRPI0506635A (pt) 2007-05-08
DE602005017016D1 (de) 2009-11-19
EP1722229A1 (en) 2006-11-15
WO2005076000A1 (es) 2005-08-18
ATE445163T1 (de) 2009-10-15
CA2555783A1 (en) 2005-08-18
MXPA06008799A (es) 2007-04-17

Similar Documents

Publication Publication Date Title
WO2005076000A8 (es) Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2007112012A3 (en) Protein isoform discrimination and quantitative measurements thereof
WO2008060651A8 (en) Sparc and methods of use thereof
WO2006098772A3 (en) Systems and methods for measurement optimization
WO2008008785A3 (en) Ultra-sensitive detection of analytes
WO2010061283A8 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2002046746A3 (en) Method for detection of vitamin d metabolites
EP1956372A4 (en) ULTRA-HIGH RESPONSE FOR DETERMINING C REACTIVE PROTEIN AND DETERMINATION METHOD
WO2007025044A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2004012588A3 (en) Use of biomarkers for detecting ovarian cancer
WO2005074541A3 (en) Detection of biological and chemical agents
WO2008011158A3 (en) Method of detecting and/ or measuring hepcidin in a sample
WO2008106648A3 (en) Immunoassays exhibiting a reduction in prozone phenomena
IL177239A0 (en) Monoclonal antibody based biomarker discovery and development platform
PL2185937T3 (pl) Sposób wykrywania posocznicy u ludzi
WO2008073425A3 (en) High-sensitivity proteolysis assay
WO2007126901A3 (en) Apparatus and method for predicting disease
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2006020567A3 (en) Method for diagnosing obstructive sleep apnea
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
WO2005050203A3 (en) The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
WO2006076371A3 (en) Method of quantitative immunohistochemistry and in situ hybridization
FR2918755B1 (fr) Procede de detection et de quantification d'analytes sur support solide avec des molecules fluorescentes encapsulees dans des immunoliposomes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT IN ENGHISH REPLACED BY CORRECT ABSTRACT

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/008799

Country of ref document: MX

Ref document number: 2555783

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006551864

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005210776

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580006853.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005701698

Country of ref document: EP

Ref document number: 2006132064

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005210776

Country of ref document: AU

Date of ref document: 20050203

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007141625

Country of ref document: US

Ref document number: 10588740

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005701698

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0506635

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10588740

Country of ref document: US